



## Keenova Therapeutics to Report Fourth-Quarter 2025 Financial Results on March 31, 2026

March 16, 2026

**DUBLIN, March 16, 2026 /PRNewswire/** -- Keenova Therapeutics plc, a leading global developer and manufacturer of branded therapeutics, announced today that it will report its fourth-quarter 2025 financial results on Tuesday, March 31, 2026, before market open. The Company will host a conference call on the same day at 8:00 a.m. ET.

The audio webcast may be accessed through the Investor Relations section of the Company's website at [investor.keenova.com](https://investor.keenova.com) under Events & Presentations through this [webcast link](#). To access the call through a conference line, participants can [register here](#) to receive a dial-in number and personalized PIN to participate in the call. Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event.

### **About Keenova**

Keenova Therapeutics is a leading global developer and manufacturer of branded therapeutics that strives to help patients with rare or unaddressed conditions live happier and healthier lives.

Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, orthopedics, urology, neonatal respiratory critical care, nephrology, neurology, and pulmonology.

Globally headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visit [www.keenova.com](http://www.keenova.com).

Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

### **Contacts:**

Media: Investors:

[media.relations@keenova.com](mailto:media.relations@keenova.com)

[investor.relations@keenova.com](mailto:investor.relations@keenova.com)

SOURCE Keenova Therapeutics